( 72.2) 199 4.6 (4.3 5.0)--...)New England Journal of Medicine Publishes New Data on Gardasil,,Merck's Cervical Cancer Vaccine,Health

, 72.2) 199 4.6 (4.3, 5.0) ---------------------------------------------------------------------- Month 36 196 59.7 (48.5, 73.5) 193 4.8 (4.4, 5.2) ---------------------------------------------------------------------- * The PPI population consisted of individuals who received all 3 vaccinations within pre-defined day ranges, did not have major deviations from the study protocol, met predefined criteria for the interval between the Month 6 and Month 7 visit, and were naive (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1 and through 1 month Postdose 3 (Month 7). **Number of subjects randomized to the respective vaccination group who received at least 1 injection. ***Number of subjects in the per-protocol analysis with data at the specified study time point. +mMU = milli-Merck units. Note: These data are from Protocol 007. ---------------------------------------------------------------------- Table 4 compares anti-HPV GMTs 1 month Postdose 3 among subjects who received Dose 2 between Month 1 and Month 3 and subjects who received Dose 3 between Month 4 and Month 8 (Table 4). Table 4 Summary of GMTs for Variation of Dosing Regimen ---------------------------------------------------------------------- Anti-HPV 6 Anti-HPV 11 Variation of Dosing ----------------------------------------- Regimen N GMT N GMT (95% CI) (95% CI) ====================================================================== Dose 2 ---------------------------------------------------------------------- Early* 570.9 824.6 883 (542.2, 601.2) 888 (776.7, 875.5) ------------------------------------------------------------
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
Related medicine technology :

1. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
2. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
3. Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
4. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
5. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
6. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
7. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
8. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
9. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
10. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics